Bio News
The U.S. Food and Drug Administration (FDA) approved Eli Lilly’s Jaypirca as a first-line treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
In the phase 3 BRUIN CLL-313 trial, Jaypirca reduced the risk of disease progression or death by 80% compared with bendamustine plus rituximab.
With the approval, Eli Lilly can now use Jaypirca across all stages of CLL/SLL treatment.
BIOBOOK TEAM
biobookmedia@biobook.co.krAspen Neuroscience and Bambusa Plan U.S. IPOs; Developers of Parkinson’s and Bispecific Antibody Therapies
St. Jude Identifies Cell Marker for High-Risk Neuroblastoma
University of Texas at Austin Develops Flexible Electrode for Recording Brain Waves for a Month Without Shaving Hair
Revolution Medicines Shares Fall 6.3% on Concerns About RASONK’s KRAS Subgroup
GSK Adopts Chai Discovery AI Model After Wet-Lab Validation
Teva Wins FDA Approval for Long-Acting Olanzapine Beltruzza for Schizophrenia
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
